1

BrainStorm is a leading developer of stem cell technologies to provide treatments for currently incurable neurodegenerative diseases. The Company is focused on developing NTF cells from the patient's own bone marrow in order to treat, Parkinson, ALS, and Spinal Cord Injury. BrainStorm Cell Therapeutics Inc. (OTCBB: BCLI)

3  Large and growing population of Parkinson Disease patients (4 M in the Western world).  Heavy social burden (according to NINDS, $26B in the U.S. annually).  Disease anatomy and pathology is well known, although causes are still obscure.  Affects a clearly defined region of the brain, the substantia nigra. Parkinson Disease PD is a degenerative disorder of the central nervous system (loss of dopamine-containing nerve cells) that often impairs the sufferer's motor skills, speech and other functions.loss of dopamine-containing nerve cells motor skills, speech and other functions

4 Amyotrophic Lateral Sclerosis Disease  5,600 people in the U.S. are diagnosed with ALS Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) each year. Total 30,000 patients in the US. & 100,000 around the world.  Fatal progressive loss of motor neurons in brain and spinal cord.  Leads to gradual loss of movement ability, culminating in death.  One approved drug – Rilutek (Riluzole) affords only an additional few months of life.  Pressing need for new effective therapies. ALS (sometimes called Lou Gehrig's disease) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.motor neuronsvoluntary muscle

Cell technologies may offer a major improvement over medication, as they target the diseased cell or organ and replace it with a healthy alternative. Advantage of Cell Therapy

Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, that multiply by cell division to replenish dying cells and regenerate damaged tissues. Adult Stem Cells (From Bone Marrow) Advantages: Non tumor forming. More than 40 years safety record. Harvested from patient – therapy does not require immunosupression. Unlike embryonic stem cells, the use of adult stem cells in research and therapy is not considered to be controversial as they are derived from adult tissue samples rather than human embryos.embryonic stem cells controversial 6

7 Brainstorm’s strategy Bone marrow aspiration Into neurotrophic factors (NTF) secreting cell BrainStorm Patent BrainStorm know-how Autologous Bone Marrow-derived Stem Cell Therapy NurOwn™ Therapeutic Technology

3. PCT covering methods of generating GDNF-producing cells from bone marrow stem cells; Currently in national phase 2.PCT covering methods of generating oligodendrocytes from bone marrow stem cells; Currently in national phase Intellectual Property 1.PCT covering methods of generating Dopamine-producing neural cells from bone marrow stem cells; Currently in national phase (Patent granted in Singapore) 8  Trademark filed for NurOwn TM in the US  3 Patents pending NTF cells Oligodendrocyte Neuron Bone Marrow Stem Cells

Business Model NurOwn TM Neurosurgery: NurOwn™ Cells implantation Hematology: Bone Marrow aspirate Insurance payment to medical center Patient population Medical center purchases BrainStorm cell processing services 9

BrainStorm Financial Summary  Stock Symbol: OTCBB:BCLI  Shares outstanding: 55.3M  Current price of stock : ~ $0.1  52 week price range: $0.07-$0.76  Market capitalization: ~ $5M  Approximate Public Float: 17M shares  Monthly current burn rate : $150K  Seeking for $10M to complete phase I and II clinical trials in ALS and phase I clinical trials in Parkinson. 10

11 Safe Harbor Disclaimer This presentation may contain certain ‘forward-looking statements’. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. The forward-looking statements included in this presentation are also subject to a number of material risks and uncertainties. We caution investors not to place undue reliance on the forward- looking statements contained in this presentation. We would advise reading our annual report filed with the United States Securities and Exchange Commission on Form 10-K for a more detailed description of these risks.

12